Patel Sanj K 4

What Happened

• Sanj K. Patel, Chairman & CEO of Kiniksa Pharmaceuticals (KNSA), exercised optioned shares and sold the resulting shares across April 28–30, 2026. He exercised a total of 508,339 shares (multiple option tranches) by paying roughly $6.84M and sold the 508,339 shares in multiple block trades for total proceeds of about $26.42M. The net cash from these transactions is approximately $19.58M. The filing shows option exercises (transaction code M) immediately followed by open-market sales (transaction code S).

Key Details

• Dates: Transactions reported for 2026-04-28 through 2026-04-30; Form 4 filed 2026-04-30.
• Exercises (paid): 508,339 shares total — examples: 431,904 @ $10.36 ($4,474,525) and 51,750 + 22,544 + 2,141 @ $30.93 (total $2,364,135); total exercise cost ≈ $6,838,660.
• Sales (proceeds): 508,339 shares total sold in multiple trades — aggregated proceeds ≈ $26,415,227 (per-line weighted averages shown in filing).
• Net proceeds: ≈ $19,576,567 (proceeds minus exercise cost).
• Footnotes: Filing notes at least some transactions were effected pursuant to a 10b5-1 plan executed Oct 31, 2025. Sales were executed in multiple trades at the price ranges reported (per footnotes). The options exercised were fully vested (per filing).
• Shares owned after transaction: not specified in the materials provided in this summary (refer to the Form 4 for the reported post-transaction holdings).
• Transaction codes: M = option exercise/conversion; S = open-market sale.

Context

• The pattern—exercising vested options and immediately selling the resulting shares—functions like a cashless exercise (exercise then sale) and is commonly used to cover exercise cost/taxes or monetize vested equity. This filing is factual reporting of those actions; it does not state the insider’s motives.